Skip to main content

Adding tucatinib to T-DM1 improves PFS: data from HER2CLIMB-02 trial

Intervista a Sara A. Hurvitz By 6 Dicembre 2023No Comments
Congressi

A combination of two HER2-targeted drugs, tucatinib and trastuzumab emtansine (T-DM1) extended progression-free survival among patients with unresectable locally advanced or metastatic HER2-positive breast cancer, compared with T-DM1 alone, according to results from the HER2CLIMB-02 trial, presented at the San Antonio Breast Cancer Symposium 2023. We asked Sara A. Hurvitz (Senior Vice President and Director of Clinical Research Division – Fred Hutchinson Cancer Center, Seattle) why these data are so important.